{"id":"NCT05194124","sponsor":"Rhythm Pharmaceuticals, Inc.","briefTitle":"Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway","officialTitle":"A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-12-21","primaryCompletion":"2023-10-19","completion":"2023-10-19","firstPosted":"2022-01-18","resultsPosted":"2024-11-26","lastUpdate":"2024-11-26"},"enrollment":19,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Bardet-Biedl Syndrome","POMC Deficiency"],"interventions":[{"type":"DRUG","name":"Setmelanotide 2 mg","otherNames":[]},{"type":"DRUG","name":"Setmelanotide 2.5 mg","otherNames":[]},{"type":"DRUG","name":"Setmelanotide 3 mg","otherNames":[]},{"type":"DRUG","name":"Setmelanotide 20 mg","otherNames":[]},{"type":"DRUG","name":"Setmelanotide 25 mg","otherNames":[]},{"type":"DRUG","name":"Setmelanotide 30 mg","otherNames":[]}],"arms":[{"label":"Run-in Period: Setmelanotide 2 mg QD","type":"EXPERIMENTAL"},{"label":"Run-in Period: Setmelanotide 2.5 mg QD","type":"EXPERIMENTAL"},{"label":"Run-in Period: Setmelanotide 3 mg QD","type":"EXPERIMENTAL"},{"label":"DB Period: Setmelanotide 20 mg QW","type":"EXPERIMENTAL"},{"label":"DB Period: Setmelanotide 25 mg QW","type":"EXPERIMENTAL"},{"label":"DB Period: Setmelanotide 3 mg QD","type":"EXPERIMENTAL"},{"label":"DB Period: Setmelanotide 30 mg QW","type":"EXPERIMENTAL"},{"label":"OL Period: Setmelanotide 20 mg QW","type":"EXPERIMENTAL"},{"label":"OL Period: Setmelanotide 25 mg QW","type":"EXPERIMENTAL"},{"label":"OL Period: Setmelanotide 30 mg QW","type":"EXPERIMENTAL"}],"summary":"A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway.","primaryOutcome":{"measure":"Maximum Drug Concentration (Cmax) of Setmelanotide After QD Administration in the Run-in Period","timeFrame":"Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose at Week -1","effectByArm":[{"arm":"Setmelanotide 2 mg QD","deltaMin":29.4,"sd":3.49},{"arm":"Setmelanotide 2.5 mg QD","deltaMin":44.8,"sd":null},{"arm":"Setmelanotide 3 mg QD","deltaMin":59.9,"sd":29.6}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":7,"countries":["United States","Canada","Germany","Netherlands","Puerto Rico","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":2},"commonTop":["Injection site pain","Injection site erythema","Injection site induration","Nasopharyngitis","Injection site haemorrhage"]}}